Names
Asparlas® Calaspargase pegol-mknlIndications and usage
Calaspargase pegol-mknl is FDA approved as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.
Side effects needing medical attention
The most common adverse reactions were elevated transaminase (a liver enzyme), bilirubin increased, pancreatitis and abnormal clotting.